Kainate receptors: an interplay between excitatory and inhibitory synapses  by Lerma, Juan
Minireview
Kainate receptors: an interplay between excitatory and
inhibitory synapses
Juan Lerma*
Instituto Cajal, Consejo Superior de Investigaciones Cient|Ł¢cas, Av. Doctor Arce 37, 28002-Madrid, Spain
Received 9 April 1998
Abstract The potent excitatory amino acid glutamate mediates
its excitatory effects through a great variety of specific
ionotropic receptors, including NMDA, AMPA and kainate
receptors. Despite the identification, isolation and cloning of
several subunits of the kainate receptor, this receptor has been
rather elusive and its function remains enigmatic. Recent results
indicate that kainate receptors can be reached by synaptically
released glutamate and that their activation downregulates
GABAergic inhibition by modulating the reliability of GABA
synapses. Thus, kainate receptors may have a role in the etiology
of epilepsy and could become a target for antiepileptic drugs.
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1. Introduction
Glutamate receptors are an important part of the signal
transduction machinery in the central nervous system. A num-
ber of glutamate receptor types, belonging to several subfami-
lies, have already been described, cloned and characterized
following their expression in heterologous systems (see [1,2]
for reviews). It has been established that the subunits GluR1^
4 (A^D) are constituents of the AMPA receptors, whereas
GluR5^7, KA1 and KA2 may comprise the so-called kai-
nate-selective (or kainate-preferring) receptor class. Until
very recently, the lack of pharmacological tools to discrimi-
nate between AMPA and kainate receptors (see [3]) caused
confusion regarding the functionally distinct actions mediated
by each receptor. This, in part, is the reason why the kainate
receptor is less well understood than other types of glutamate
receptor and its detection as a functional entity in CNS neu-
rons has been di⁄cult. Now, there is a body of evidence in-
dicating that functional kainate receptors are expressed by
brain cells. However, until now most of the described e¡ects
of kainate in the CNS are most probably mediated by its
action on AMPA receptors, since these receptors desensitize
less when activated by kainate than the kainate-selective re-
ceptors (Fig. 1). Consequently, the physiological role of kai-
nate speci¢c receptors is just starting to be documented [4^8].
2. Properties of kainate receptors
2.1. Assembly possibilities
Since ¢ve subunits of kainate receptors have been cloned, a
number of possible combinations can give rise to a receptor.
However, not all of them render functional channels. GluR5
forms receptors that can be activated by kainate, domoate
and AMPA [9,10]. These receptor channels desensitize slowly
when activated by kainate but when the agonist is glutamate
desensitization is faster and almost complete. In contrast,
GluR6 generates homomeric channels showing fast desensitiz-
ing kinetics when activated by either agonist (Fig. 1B). Unlike
the GluR5 receptors, GluR6 homomeric channels are not
sensitive to AMPA [11,12]. Recently, it has been demon-
strated that GluR7 subunits can also form functional homo-
meric receptors [13]. Interestingly, these receptors have very
low a⁄nity for glutamate and are insensitive to AMPA and
domoate. Combinations of GluR5 with GluR6 or GluR7 are
unable to render heteromeric channels in heterologous sys-
tems and nervous cells. However, each of these subunits forms
heteromeric receptors when coexpressed with KA1 or KA2,
giving rise to ion channels with distinct properties. The inclu-
sion of KA subunits into GluR6 or GluR7 receptors makes
them sensitive to AMPA [12,13] while heteromeric GluR5-
KA2 receptors present faster inactivation kinetics than homo-
meric GluR5 channels. The kainate receptor subunits also
present a variation generated by edition of the pre-mRNA
at the so-called Q/R site of the second membrane domain
(see [14] for a review). The subunit GluR6 presents two addi-
tional sites susceptible to edition in the ¢rst transmembrane
domain (M1). Although the participation of the Q/R site in
the control of Ca permeability is well established in func-
tional kainate and AMPA receptors [15], the role of the M1
editing sites remains obscure.
2.2. Receptor types functionally described
The anatomical distribution of kainate receptor subunits
has been determined by in situ hybridization (e.g. [16,17]).
Although no entirely speci¢c antibodies are available, numer-
ous studies have also contributed to our knowledge of the
distribution of kainate receptor in the brain (e.g. [18^20]).
With a few exceptions, all ¢ve subunits are expressed by the
majority of brain cells. However, not all of these possible
combinations have been demonstrated to be present in neu-
rons as functional entities. Seven years ago, Huettner [21]
observed kainate induced responses in dorsal root ganglion
(DRG) neurons that di¡ered from those previously recorded.
The receptors mediating these responses presented higher ap-
parent a⁄nity for either kainate or domoate, and underwent
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marked desensitization (see Fig. 1A). DRG cells heavily ex-
press the subunit GluR5 and GluR5-de¢cient mice lose the
kainate induced responses in these cells [22]. Taking into ac-
count the functional properties and binding a⁄nities of di¡er-
ent receptors, it could be concluded that these receptors
mostly correspond to homomeric GluR5 constructs. Func-
tional receptors selective for kainate have also been demon-
strated in cultured hippocampal neurons [23,24] and glial cells
[25]. In these two types of cells, kainate induced rapidly acti-
vating and inactivating currents. These responses could also
be elicited by glutamate, quisqualate and the potent mussel
toxin domoate. RT-PCR at the single cell level, showed that
these receptors contained the GluR6 subunit [26] (see also
[25]). The kainate receptor of cultured embryonic hippocam-
pal cells is insensitive to AMPA, although in cultures from
postnatal neurons, a high concentration of AMPA alone elic-
ited a response compatible with the inclusion of KA subunits
in the receptor. The variation of subunit expression during
development may account for this fact. More recently, func-
tional kainate receptors with properties compatible with
GluR5/KA2 heteromers have been found in rat trigeminal
neurons [27].
2.3. Pharmacological aspects
Until very recently, the lack of speci¢c pharmacological
agents discriminating kainate from AMPA receptors has pre-
cluded their functional study. Indeed, AMPA and kainate
receptors coexist in neurons [23] and the available agonists
(e.g. kainate, domoate) are poorly selective so that both kai-
nate and AMPA receptors are simultaneously activated. In
addition, the prototypic competitive antagonist of AMPA re-
ceptors, CNQX, also antagonizes kainate receptors although
less potently [28,29]. The compound NS102, initially believed
to be more speci¢c for kainate receptors [22,30] actually
showed a poor selectivity in preventing the action of kainate
on AMPA and kainate receptors. Although a new generation
of compounds are currently being produced [31^33], in gen-
eral, the lack of complete selectivity amongst available com-
petitive antagonists for AMPA or kainate receptors is gener-
ally accepted. However, the separation of kainate receptor-
mediated responses from the AMPA receptor-mediated cur-
rents is now possible thanks to the availability of a number of
new compounds. One of these (GYKI 53655; also LY300168),
which belongs to the 2,3-benzodiazepines family initially de-
veloped by Ivstan Tarnawa and associates (see [3]), is selective
for AMPA receptors and has made possible the functional
isolation of kainate receptors [34]. This drug has allowed us
to isolate kainate receptor-mediated currents in cultured neu-
rons (Fig. 1C) and slices (see below). Taking advantage of this
pharmacological tool, a number of experiments have been
performed, aimed at clarifying some aspects of the kainate
receptor functioning.
3. Searching for roles of kainate receptors
3.1. To mediate synaptic transmission
Whereas the role of AMPA receptors in fast synaptic trans-
mission is well characterized, the synaptic responses due to the
activation of kainate receptor channels has proven di⁄cult to
demonstrate (see [3] for a review). However, two groups have
recently demonstrated a synaptically triggered response in the
CA3 pyramidal neurons of the hippocampus upon repetitive
stimulation of the mossy ¢bers [4,7]. Such synaptic responses
have a pharmacological pro¢le consistent with the activation
of kainate receptors. This means that synaptically released
glutamate has access to postsynaptically localized kainate re-
ceptors. However, this may only occur in certain circumstan-
ces, like repetitive presynaptic activity and might re£ect the
glutamate spillover from adjacent synapses (Figs. 2 and 3).
Although the functional implication for these synaptic re-
sponses has not yet being established, it opens some possibil-
ities for the physiological functions of kainate receptors. The
¢nding that only repetitive stimulation of the mossy ¢bers
evokes a kainate receptor-mediated response on CA3 pyrami-
dal cells is in keeping with the high expression of kainate
receptor subunits in this area, as well as with the selective
depolarizing action of kainate when applied to the stratum
lucidum. Interestingly, the synaptic current induced by a train
of stimuli was not apparent in mice in which the GluR6 gene
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Fig. 1. Responses induced by glutamate receptor agonists. A: Acti-
vation of kainate receptors expressed by dorsal root ganglion
(DRG) cells by rapid application of kainate (300 WM) and gluta-
mate (1 mM; bars above the records). These kainate receptors
mostly correspond to GluR5 formations [10]. B: Responses induced
by kainate and glutamate in an HEK cell which had been trans-
fected with GluR6 cDNA. Note that response kinetics notably di¡er
from those obtained in the DRG cell. C: Responses activated by
AMPA (200 WM) and kainate (300 WM) in hippocampal neurons
are more complex. AMPA activates a response that largely desensi-
tizes. The same neuron develops a slowly rising non-desensitizing
current when the agonist is kainate (2nd record). Both responses are
due to the activation of AMPA receptors. The existence of kainate
receptors in this cell, may be revealed after desensitizing AMPA re-
ceptors by a high concentration of AMPA (3rd record, the initial
response is truncated), and rapidly jumping into a kainate contain-
ing solution [23,28]. The peak response at the beginning of the kai-
nate perfusion revealed the presence of kainate receptors. The subse-
quent slowly developing current represents the activation by kainate
of AMPA receptors as they recover from the desensitized state. The
total antagonism of AMPA receptors by GYKI 53655 (100 WM) un-
masks the presence of the kainate induced response, which consists
of a rapid activating and inactivating current (4th record) [34]. Ver-
tical calibrations in this panel are 300, 400, 50 and 30 pA, respec-
tively.
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had been disrupted [35]. This result indicates that kainate
receptors containing the GluR6 subunit participate in some
way to the synaptic transmission at this synapse. Obviously,
these data provide a physiological foundation for the selective
distribution of high-a⁄nity kainate binding sites to this area
of the hippocampus.
3.2. To modulate synaptic transmission: the interplay between
glutamate and GABA synapses
Two years ago, it was shown that kainate produced a de-
crease in 3H-glutamate release from hippocampal synapto-
somes [36]. The same group showed a reduction of the
NMDA receptor-mediated component of CA1 synaptic re-
sponses when hippocampal slices were perfused with a low
concentration of kainate. Although these results indicated a
participation of kainate receptors in controlling the synaptic
release of glutamate, they were somewhat surprising since they
are in clear contradiction to the well known action of kainate
as a potent convulsing excitotoxin in the CNS. Indeed, several
authors had reported that kainate, even at low concentrations,
induced a general increase of excitability sometimes conveying
epilepsy [36^40].
A more consistent functional implication for kainate recep-
tors in synaptic integration has recently come to the light,
through the use of GYKI 53655 and other compounds. Two
reports have shown that kainate receptor activation downreg-
ulates GABAergic inhibition in hippocampal CA1 pyramidal
neurons [5,6]. A number of experimental protocols (e.g. anal-
ysis of synaptic failures; the representation of normalized var-
iance vs. the normalized mean; analysis of miniature IPSCs,
etc.) revealed a presynaptic mode of action for kainate (see
Fig. 2). Additionally, Clarke et al. [5] found this same result
by using a new compound, ATPA (2-amino-3-(3-hydroxy-5-
tert-butylisoxazol-4-yl)propanoic acid), that seems to selec-
tively activate GluR5 containing receptors. Several subunits
of the kainate type may coexist within the same cell (e.g.
GluR5 and GluR6; see [26]). Moreover, the combined use
of ATPA and the GluR5 speci¢c antagonist, LY294486 [5],
has not yet been evaluated on the kainate receptors expressed
by hippocampal cells. However, in principle, these results in-
dicate that activation of GluR5 subunits inhibits GABA re-
lease in the hippocampus (but see below).
3.3. The role in epilepsy
Whatever the subunit involved in the modulation of GABA
release, the results indicate that kainate receptors may have a
role in the etiology of epilepsy. In vivo experiments carried
out in rats in which a microdialysis probe had been implanted
in the hippocampus, demonstrated that low concentrations of
kainate produced a ¢ring pattern reminiscent of status epilep-
ticus, concomitantly attenuating the extent of GABAergic in-
hibition. This activity was correlated with the presence of
epileptic spikes in hippocampal electrical activity [6]. It is
well known that similar spikes appear in vivo and in slices
after exposure to convulsants that block GABA-mediated in-
hibition. In relation to this, allelic variants of the human
GluR5 kainate receptor gene (GRIK1) have recently been
associated with susceptibility to juvenile absence epilepsy, a
common subtype of idiopathic generalized epilepsy which ac-
counts for 5% of all epilepsies [41]. The functional character-
istics of the receptors encoded by these alleles are unknown.
However, it might be anticipated that the responsible allele
generates a hyperfunctioning kainate receptor. All these re-
sults implicate kainate receptors in the pathogenesis of epi-
lepsy and it is very likely that the interference with GABAer-
gic transmission is the reason why kainate and related
compounds are such potent epileptogenic agents. Indeed,
GluR6-de¢cient mice are much less susceptible to develop
seizures induced by systemic injections of kainate [35] than
normal animals. This result, however, would favor the partic-
ipation of GluR6 rather than GluR5 in the control of GABA
release.
3.4. Could kainate receptors be a target for anticonvulsant
drugs?
It can be demonstrated that the e¡ectiveness of both kai-
nate and glutamate for reducing GABAergic transmission in
hippocampal slices is in keeping with the bell-shaped curve
predicted from studies on kainate receptors expressed by hip-
pocampal cells in culture [6,42]. Thus, kainate receptors mod-
ify the strength of the inhibitory connections within a precise
extracellular concentration range of glutamate, a fact that
endows tuning properties to these receptors (i.e. e¡ective
steady state receptor activity is achieved by some but not all
concentrations of glutamate). This aspect of kainate receptor
modulation is relevant in terms of their physiological and/or
pathological activity, since variations in the extracellular con-
centration of glutamate within the active range might occur
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Fig. 2. Kainate modulates the reliability of GABAergic transmission
in the hippocampus. A: Schematic representation of the experimen-
tal setup: electrical stimuli were delivered via a bipolar electrode on
the stratum oriens, while evoked inhibitory synaptic currents were
recorded from identi¢ed pyramidal neurons, which were kept at
360 mV holding membrane potential. Note how in the presence of
kainate, the mean amplitude of the IPSC decreases and the number
of transmission failures increases. The increase in failures was corre-
lated with the magnitude of IPSC reduction (B; P6 0.01). Dashed
lines correspond to the 95% con¢dence interval. C: E¡ect of kainate
on the trial to trial £uctuation of the evoked IPSCs. Mean IPSC
amplitude and its coe⁄cient of variation (CV) were measured dur-
ing kainate application and normalized by the respective control
value in each cell. The fractional variation in amplitude (M) vs. the
fractional variation in 1/CV2 are plotted irrespective of the concen-
tration of kainate used. Note that experimental data follow the pre-
dicted relation for a purely presynaptic (dashed line) rather than
postsynaptic (dotted line) action. Adapted from [6].
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during intense neuronal activity and/or ischemic episodes [43].
Indeed, a glutamate concentration of about 100 WM, which
has been estimated to be the concentration reached in the
extracellular £uid during transient ischemic episodes [44], co-
incides with the concentration most e¡ective in decreasing the
release of GABA [45]. Whether this is relevant or not for the
e¡ects of ischemia (epilepsy, tissue lesions, etc.) is something
that remains to be investigated. However, the mutant mice
lacking the astrocytic glutamate transporter, GLT-1, show
lethal spontaneous seizures and selective neuronal degenera-
tion in the hippocampal CA1 ¢eld [46]. Although the extra-
cellular concentration of glutamate has not been measured in
these mutant mice, the peak concentration of synaptically
released glutamate was increased in these mice and the time
that glutamate remained elevated in the extracellular £uid was
also prolonged. If GABA synapses are under the control of
kainate receptors, then the release of GABA would be com-
promised in these mice by excessive kainate receptor activity.
In this situation, one would expect exacerbation of both seiz-
ure and toxicity sensitivity, e¡ects that hypothetically would
be prevented by antagonizing kainate receptors. Although this
is presently a rather speculative idea, it provides a rationale
with which to explore the possibility that drugs antagonizing
kainate receptors can act as e¡ective anticonvulsants.
4. Perspectives
4.1. Physiology and null mutants
Whatever their subunit composition, it seems clear that
kainate receptors modify the reliability of GABAergic synap-
ses, thus modifying the strength of inhibitory connections in
the hippocampus. This means that an interplay between ex-
citatory and inhibitory synapses exists in the hippocampus
such that glutamate can modify the strength of inhibitory
connections. It will be important to establish whether this
kind of modulation also occurs under physiological condi-
tions, i.e. that endogenous glutamate has the same action. It
would also be crucial to establish under what circumstances
this happens. The availability of speci¢c drugs as well as of
knockout mice for each of the kainate receptor subunits will
soon permit the clari¢cation of which subunit participates in
speci¢c kainate-mediated responses. For instance, it would be
expected that the targeted disruption of the kainate receptor
subunit responsible for the inhibition of GABA release will
produce a ‘quiet’ mouse [8], since its phenotypic behavior
should be consistent with GABAergic hyperactivity. Although
the behavioral analysis of GluR6 null mutants did not reveal
any de¢cits in sensorimotor tests, the locomotor activity was
reduced in the mutant. This is consistent with the predicted
‘quietness’ induced by a potentiation of GABAergic activity.
Unfortunately, there are no behavioral data for the GluR5-
de¢cient mice so far. Obviously, the detailed analysis of kai-
nate receptor mutant mice at several levels, cellular, physio-
logical and behavioral, will be most useful in identifying phys-
iological processes in which kainate receptors play a role. As
Mayer [47] recently pointed out, with the new data in mind we
are forced to revise the current picture on how glutamate acts
as a synaptic transmitter.
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Fig. 3. Kainate receptor function in the hippocampus. In the CA1 region of the hippocampus, glutamate spillover during single or repetitive ac-
tivation of glutamatergic synapses ^ Scha¡er collaterals ^ may in£uence GABAergic terminals and activate presynaptic kainate receptors. Some
evidence suggests that these may include GluR5 or GluR6 subunits [5,6]. Repetitive activation of glutamatergic synapses and/or reduction of
glutamate clearance may be expected to have a striking e¡ect on the reliability of GABAergic synapses. In addition, according to recent re-
ports, high-frequency stimulation of mossy ¢bers may activate postsynaptic kainate receptors in the CA3 ¢eld of the hippocampus [4,7].
Although it needs further substantiation, such a result would be compatible with an extrasynaptic localization of kainate receptors, which under
special circumstances, like repetitive activity of mossy ¢bers, would be reached by the glutamate overspill. According to data from the null mu-
tant mice [35], these receptors include GluR6 subunits.
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